Clinical trial / 2024
A 20-week intensive multidomain lifestyle intervention improved cognition, function, and biomarkers in patients with MCI or early AD dementia.
A 1:1 randomized controlled trial evaluated the effects of a 20-week intensive multidomain lifestyle intervention versus a wait-list usual care control group in 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease. After 20 weeks, significant between-group differences favored the intervention group in CGIC (p = 0.001), CDR-SB (p = 0.032), and CDR Global (p = 0.037), with borderline significance for ADAS-Cog (p = 0.053). The intervention group improved on CGIC, CDR Global, and ADAS-Cog and had significantly less progression on CDR-SB, while the control group worsened on all four measures. Plasma Aβ42/40 ratio increased in the intervention group and decreased in controls (p = 0.003), and the microbiome improved only in the intervention group (p < 0.0001).
- Study type
- Multicenter randomized controlled trial
- Who was studied
- 51 patients aged 45-90 (mean age 73.5) with MCI or early dementia due to AD
- What was measured
- Cognition and function tests (CGIC, ADAS-Cog, CDR-SB, CDR-G) at 20 weeks; secondary outcomes included plasma Aβ42/40 ratio and microbiome changes
THE PAPER
Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
Ornish D, Madison C, Kivipelto M, Kemp C, McCulloch CE, Galasko D, Artz J, Rentz D, Lin J, Norman K, Ornish A, Tranter S, DeLamarter N, Wingers N, Richling C, Kaddurah-Daouk R, Knight R, McDonald D, Patel L, Verdin E, E Tanzi R, Arnold SE. Alzheimers Res Ther, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.